MORGAN STANLEY PLC/CALL/ASTRAZENECA ADR/97.5/0.1/20.12.24 | Market Closed - Börse Stuttgart 20:00:52 14/06/2024 BST | ||
| 0.098 EUR | +2.08% |
|
| Current month | +28.95% | ||
| 1 month | +50.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 0.098 | +2.08% |
| 13/06/24 | 0.096 | -5.88% |
| 12/06/24 | 0.102 | +9.68% |
| 11/06/24 | 0.093 | -7.92% |
| 10/06/24 | 0.101 | +4.12% |
Delayed Quote Börse Stuttgart
Last update June 14, 2024 at 08:00 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MB5R9N |
| ISIN | DE000MB5R9N7 |
| Date issued | 20/04/2023 |
| Strike | 97.5 $ |
| Maturity | 20/12/2024 (188 Days) |
| Parity | 10 : 1 |
| Emission price | 0.37 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.35 € |
|---|---|
| Lowest since issue | 0.005 € |
| Spread | 0.003 € |
| Spread % | 2.94% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
158.6
USD
Average target price
174.4
USD
Spread / Average Target
+9.95%
- Stock Market
- Warrants
- Warrant
